Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1B | Q92523 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9015998 | 0.96 | CPT1B (0.93) | CPT1BTDP1MEN1KMT2AKDM4E | |
| Fumaric Acid SCHEMBL29802140 | 0.93 | CPT1B (0.86) | CPT1BTDP1MEN1KMT2AKDM4E | |
| SCHEMBL9015962 | 0.86 | CPT1B (0.75) | CPT1BTDP1MEN1KMT2AKDM4E | |
| SCHEMBL9623027 | 0.85 | CPT1B (0.74) | CPT1BTDP1MEN1KMT2AKDM4E | |
| SCHEMBL9015995 | 0.85 | CPT1B (0.74) | CPT1BTDP1MEN1KMT2AKDM4E | |
| SCHEMBL9015960 | 0.84 | CPT1B (0.73) | CPT1BTDP1MEN1KMT2AKDM4E | |
| SCHEMBL9015980 | 0.84 | CPT1B (0.73) | CPT1BTDP1MEN1KMT2AKDM4E | |
| SCHEMBL9015974 | 0.84 | CPT1B (0.73) | CPT1BTDP1MEN1KMT2AKDM4E | |
| SCHEMBL9015971 | 0.83 | CPT1B (0.70) | CPT1BTDP1MEN1KMT2AKDM4E | |
| SCHEMBL9622314 | 0.82 | CPT1B (0.69) | CPT1BTDP1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000935-A1 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2024-01-04 | — | — | US | claimed |
| EP-4251177-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | Geneius Biotechnology, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| US-20230218608-A1 | NEW STRATEGY FOR TREATING PANCREATIC CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2023-07-13 | — | — | US | claimed |
| EP-4168006-A1 | NEW STRATEGY FOR TREATING PANCREATIC CANCER | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2023-04-26 | — | — | EP | claimed |
| WO-2022115641-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| US-5283246-A | Trimetazidine compounds | ADIR ET COMPAGNIE (FR) | 1994-02-01 | — | — | US | claimed |
| US-20260076926-A1 | COMPOUNDS FOR USE IN ORGAN PRESERVATION AND ORGAN TRANSPLANTATION | ABREXA PHARMACEUTICALS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| CN-110573610-B | Method for preparing retinal pigment epithelial cells | 住友制药株式会社 | 2025-01-28 | — | — | CN | disclosed |
| US-12195779-B2 | Methods for harvesting mammalian cell cultures | AMGEN INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-12171821-B2 | Toxoplasma gondii vaccine | WISCONSIN ALUMNI RESEARCH FOUNDATION (WARF) (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| EP-4372078-A2 | METHODS FOR HARVESTING MAMMALIAN CELL CULTURES | Amgen Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20220136025-A1 | METHODS FOR HARVESTING MAMMALIAN CELL CULTURES | AMGEN INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20100286073-A1 | COMPOUNDS AND METHODS FOR PHARMACEUTICAL USE | GENERICS (UK) LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2205229-A1 | COMPOUNDS AND METHODS FOR PHARMACEUTICAL USE | Mintails Limited (CY) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009044202-A1 | COMPOUNDS AND METHODS FOR PHARMACEUTICAL USE | MINTAILS LIMITED (CY) | 2009-04-09 | — | — | WO | disclosed |
| EP-0533579-B1 | Trimetazidine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1996-12-04 | — | — | EP | disclosed |
| US-5283246-A | Trimetazidine compounds | ADIR ET COMPAGNIE (FR) | 1994-02-01 | — | — | US | disclosed |
| EP-0533579-A1 | Trimetazidine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076926-A1 | COMPOUNDS FOR USE IN ORGAN PRESERVATION AND ORGAN TRANSPLANTATION | CASP9, CASP3, CASP10 | CPT1B 196/4885TDP1 2213/4885MEN1 4523/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | CPT1B 1897/4885TDP1 1867/4885MEN1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.